143 related articles for article (PubMed ID: 25635351)
1. Actinoallolides A-E, new anti-trypanosomal macrolides, produced by an endophytic actinomycete, Actinoallomurus fulvus MK10-036.
Inahashi Y; Iwatsuki M; Ishiyama A; Matsumoto A; Hirose T; Oshita J; Sunazuka T; Panbangred W; Takahashi Y; Kaiser M; Otoguro K; Ōmura S
Org Lett; 2015 Feb; 17(4):864-7. PubMed ID: 25635351
[TBL] [Abstract][Full Text] [Related]
2. Identification and heterologous expression of the actinoallolide biosynthetic gene cluster.
Inahashi Y; Shiraishi T; Také A; Matsumoto A; Takahashi Y; Ōmura S; Kuzuyama T; Nakashima T
J Antibiot (Tokyo); 2018 Aug; 71(8):749-752. PubMed ID: 29679043
[TBL] [Abstract][Full Text] [Related]
3. Anti-trypanosomal activities of DNA topoisomerase inhibitors.
Deterding A; Dungey FA; Thompson KA; Steverding D
Acta Trop; 2005 Mar; 93(3):311-6. PubMed ID: 15715983
[TBL] [Abstract][Full Text] [Related]
4. In vitro antitrypanosomal activity of 12 low-molecular-weight antibiotics and observations of structure/activity relationships.
Iwatsuki M; Otoguro K; Ishiyama A; Namatame M; Nishihara-Tukashima A; Hashida J; Nakashima T; Masuma R; Takahashi Y; Yamada H; Omura S
J Antibiot (Tokyo); 2010 Oct; 63(10):619-22. PubMed ID: 20717119
[No Abstract] [Full Text] [Related]
5. Compounds containing 2-substituted imidazole ring for treatment against human African trypanosomiasis.
Samant BS; Sukhthankar MG
Bioorg Med Chem Lett; 2011 Feb; 21(3):1015-8. PubMed ID: 21211967
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
Salado IG; Baán A; Verdeyen T; Matheeussen A; Caljon G; Van der Veken P; Kiekens F; Maes L; Augustyns K
Eur J Med Chem; 2018 May; 151():18-26. PubMed ID: 29604541
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
Urbaniak MD; Tabudravu JN; Msaki A; Matera KM; Brenk R; Jaspars M; Ferguson MA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5744-7. PubMed ID: 16962325
[TBL] [Abstract][Full Text] [Related]
8. Sleeping sickness pathogen (Trypanosoma brucei) and natural products: therapeutic targets and screening systems.
Hannaert V
Planta Med; 2011 Apr; 77(6):586-97. PubMed ID: 20945274
[TBL] [Abstract][Full Text] [Related]
9. Promising lead compounds for novel antiprotozoals.
Otoguro K; Iwatsuki M; Ishiyama A; Namatame M; Nishihara-Tukashima A; Shibahara S; Kondo S; Yamada H; Omura S
J Antibiot (Tokyo); 2010 Jul; 63(7):381-4. PubMed ID: 20661239
[No Abstract] [Full Text] [Related]
10. Kola acuminata proanthocyanidins: a class of anti-trypanosomal compounds effective against Trypanosoma brucei.
Kubata BK; Nagamune K; Murakami N; Merkel P; Kabututu Z; Martin SK; Kalulu TM; Huq M; Yoshida M; Ohnishi-Kameyama M; Kinoshita T; Duszenko M; Urade Y
Int J Parasitol; 2005 Jan; 35(1):91-103. PubMed ID: 15619520
[TBL] [Abstract][Full Text] [Related]
11. Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent.
Yang PY; Wang M; Liu K; Ngai MH; Sheriff O; Lear MJ; Sze SK; He CY; Yao SQ
Chemistry; 2012 Jul; 18(27):8403-13. PubMed ID: 22674877
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of selective tubulin inhibitors as anti-trypanosomal agents.
Bobba V; Nanavaty V; Idippily ND; Zhao A; Li B; Su B
Bioorg Med Chem; 2017 Jun; 25(12):3215-3222. PubMed ID: 28428042
[TBL] [Abstract][Full Text] [Related]
13. In vitro trypanocidal activity of the anti-helminthic drug niclosamide.
Merschjohann K; Steverding D
Exp Parasitol; 2008 Apr; 118(4):637-40. PubMed ID: 18226810
[TBL] [Abstract][Full Text] [Related]
14. Novel pyrrolobenzoxaboroles: design, synthesis, and biological evaluation against Trypanosoma brucei.
Wu P; Zhang J; Meng Q; Nare B; Jacobs RT; Zhou H
Eur J Med Chem; 2014 Jun; 81():59-75. PubMed ID: 24826816
[TBL] [Abstract][Full Text] [Related]
15. Arenicolides A-C, 26-membered ring macrolides from the marine actinomycete Salinispora arenicola.
Williams PG; Miller ED; Asolkar RN; Jensen PR; Fenical W
J Org Chem; 2007 Jul; 72(14):5025-34. PubMed ID: 17266372
[TBL] [Abstract][Full Text] [Related]
16. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
[TBL] [Abstract][Full Text] [Related]
17. New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents.
Demoro B; Sarniguet C; Sánchez-Delgado R; Rossi M; Liebowitz D; Caruso F; Olea-Azar C; Moreno V; Medeiros A; Comini MA; Otero L; Gambino D
Dalton Trans; 2012 Feb; 41(5):1534-43. PubMed ID: 22138896
[TBL] [Abstract][Full Text] [Related]
18. Antitrypanosomal structure-activity-relationship study of synthetic cynaropicrin derivatives.
Usuki T; Sato M; Hara S; Yoshimoto Y; Kondo R; Zimmermann S; Kaiser M; Brun R; Hamburger M; Adams M
Bioorg Med Chem Lett; 2014 Feb; 24(3):794-8. PubMed ID: 24433861
[TBL] [Abstract][Full Text] [Related]
19. Trypanosoma brucei: effects of methoprene and other isoprenoid compounds on procyclic and bloodstream forms in vitro and in mice.
Harmon MA; Scott TC; Li Y; Boehm MF; Phillips MA; Mangelsdorf DJ
Exp Parasitol; 1997 Nov; 87(3):229-36. PubMed ID: 9371088
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
